Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Patent Claims

1. (Currently Amended) A transdermal therapeutic system ~~(TTS)~~ for continuous administration of pramipexol[[,]] comprising a backing layer and at least one active ingredient-containing polymer layer which comprises the active ingredient pramipexol, wherein the active ingredient-containing polymer layer comprises at least one pressure-sensitive adhesive polymer selected from the group of silicones ~~(polydimethylsiloxanes)~~, ~~of~~ polyisobutylenes, ~~of~~ polybutenes, ~~of~~ styrene-isoprene-styrene block copolymers in combination with resins, and of carboxyl group-free polyacrylates, where the active ingredient pramipexol is present therein in a proportion of between 10 and 40 % by weight.

2. (Currently Amended) The ~~TTS~~ transdermal therapeutic system as claimed in claim 1, which comprises a further pressure-sensitive adhesive layer, an additional membrane which controls the rate of release of pramipexol, an additional active ingredient-containing layer or an additional supporting layer.

3. (Currently Amended) The ~~TTS~~ transdermal therapeutic system as claimed in claim 1 ~~or~~ ~~2~~, wherein the pressure-sensitive adhesive polymer is a carboxyl group-free polyacrylate which can be prepared by polymerization of a monomer mixture of at least one acrylic ester or methacrylic ester.

4. (Currently Amended) The ~~TTS~~ transdermal therapeutic system as claimed in claim 3, wherein the monomer mixture comprises at least one acrylic ester or methacrylic ester with linear, branched or cyclic aliphatic C_1-C_{12} substituents without other functional groups.

5. (Currently Amended) The ~~TTS~~ transdermal therapeutic system as claimed in claim 3 ~~or~~ 4, wherein the monomer mixture additionally comprises at least one hydroxyl group-containing acrylic ester or one hydroxyl group-containing methacrylic ester in a proportion by weight of less than 10 %.

6. (Currently Amended) The ~~TTS~~ transdermal therapeutic system as claimed in ~~one or more of~~ claim[[s]] 3 ~~to 5~~, wherein the monomer mixture additionally comprises vinyl acetate in a proportion by weight of less than 50 %[[,]] ~~preferably less than 25 % and particularly preferably between 0 and 5 %~~.

7. (Currently Amended) The ~~TTS~~ transdermal therapeutic system as claimed in ~~one or more of the preceding claims~~ claim 1, wherein the active ingredient pramipexol is present in the active ingredient-containing polymer layer in dissolved, emulsified and/or dispersed form.

8. (Currently Amended) The ~~TTS~~ transdermal therapeutic system as claimed in ~~one or more of the preceding claims~~ claim 1, wherein the active ingredient pramipexol is present as *S*-(-) enantiomer, *R*-(+) enantiomer or racemic mixture of these two enantiomers in the active ingredient-containing polymer layer.

9. (Currently Amended) The ~~TTS~~ transdermal therapeutic system as claimed in ~~one or more of the preceding claims~~ claim 1, wherein the active ingredient pramipexol is present as a free base, ~~as~~ hydrate, solvate and/or pharmaceutically acceptable salt in the active ingredient-containing polymer layer.

10. (Currently Amended) The ~~TTS~~ transdermal therapeutic system as claimed in ~~one or more of the preceding claims~~ claim 1, wherein the active ingredient pramipexol is present as *S*-(-) enantiomer in the form of ~~the~~ a free base in the active ingredient-containing polymer layer.

11. (Currently Amended) The ~~TTS~~ transdermal therapeutic system as claimed in ~~one or more of the preceding claims~~ claim 1, ~~which is able to deliver~~ wherein said transdermal therapeutic system delivers the active ingredient pramipexol continuously to a patient's skin over a period of from 4 to 7 days.

12. (Currently Amended) The ~~TTS~~ transdermal therapeutic system as claimed in ~~one or more of the preceding claims~~ claim 1, which is able to release the active ingredient pramipexol with a flux rate greater than 5 $\mu g/cm^2$ h over the period between 24 hours after administration to 168 h after administration.

13. (Currently Amended) The ~~TTS~~ transdermal therapeutic system as claimed in ~~one or more of the preceding claims~~ claim 1, ~~which is able to release~~ said transdermal therapeutic system releasing the active ingredient pramipexol with a flux rate greater than 5 $\mu g/cm^2$ h over the period between 24 hours after administration to 72 h after administration.

14. (Currently Amended) The ~~TTS~~ transdermal therapeutic system as claimed in ~~one or more of the preceding claims~~ claim 1, wherein the active ingredient pramipexol is present therein in a proportion of between 10 and 25 % by weight.

15. (Currently Amended) The ~~TTS~~ transdermal therapeutic system as claimed in ~~one or more of the preceding claims~~ claim 1, wherein the daily delivery rate of pramipexol is between 0.1-10 mg[[,]] ~~preferably between 0.5-4.5 mg~~.

16. (New) The transdermal therapeutic system as claimed claim 6, wherein said vinyl acetate is present in a proportion of less than 25% by weight.

17. (New) The transdermal therapeutic system as claimed claim 15, wherein the daily delivery rate of pramipexol is between 0.5 to 4.5 mg.